A phase II study of isoflavones, erlotinib, and gemcitabine in advanced pancreatic cancer.
El-Rayes BF, Philip PA, Sarkar FH, Shields AF, Ferris AM, Hess K, Kaseb AO, Javle MM, Varadhachary GR, Wolff RA, Abbruzzese JL.
El-Rayes BF, et al.
Invest New Drugs. 2011 Aug;29(4):694-9. doi: 10.1007/s10637-010-9386-6. Epub 2010 Jan 27.
Invest New Drugs. 2011.
PMID: 20107864
Clinical Trial.